

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Sotorasib for previously treated KRAS G12C mutation-  
positive advanced non-small-cell lung cancer (Managed  
Access review of TA781) [ID6287]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Consultation**

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

Statements from patients said that some people in this population may have cognitive impairments or disabilities that mean they struggle with the self-administration of sotorasib. Disability is protected under the Equality Act 2010.

The committee agreed this was not something that could be addressed in its recommendation.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee noted that not everyone is tested for KRAS mutations and so there could be inequalities in access to sotorasib across the NHS.

Because the committee's recommendation does not restrict access to treatment for some people over others, the committee agreed this was not a potential equality issues.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in section 3.19.

**Approved by Principal Technical Adviser (name):** Elizabeth Bell

**Date:** 24/02/2026